Introduction
Coronary artery chronic total occlusions (CTOs) are an exacerbation of stable coronary artery disease (CAD) with advanced calcification. CTOs are defined as 100% coronary occlusions with thrombolysis in myocardial infarction (TIMI) 0 flow persisting for > 3 months 1 .
National database registries and large single centre series suggest that in patients with CAD the overall incidence of CTOs may vary from 16-19% in Japan 2 to 29-33% in North America 3 , suggesting that this is a prevalent problem globally. Treatment of CTOs should be considered if associated with symptoms and/or viable/ischemic myocardial territories.
Historically, treatments have been via coronary artery bypass grafting (CABG) or medical therapy [3] [4] [5] [6] [7] [8] [9] .
The use of percutaneous coronary intervention (PCI) to treat CTOs (CTO-PCI) against established practice is controversial 10 . This controversy is facilitated by poor evidence available and by lack of clarity in the European and American guidelines for revascularization including those for patients with stable CAD [11] [12] [13] [14] [15] . However, the lack of robust evidence and unclear guidelines can lead to ill-defined clinical indications determining serious geographical discrepancies in CTO-PCI medical practice. In a recent report from Japan more than 61% of patients diagnosed with CTOs (19% of all CAD patients) were treated with CTO-PCI 2 . This is a significant increase compared with a previous report from North America in which only 6-9% of all CTOs (29-33% of all CAD cases) were treated with CTO-PCI (range 1% to 16% by geographical area/centre) 3 . The report by Yamamoto and coworkers 2 suggests a widespread use of CTO-PCI in patients with multivessel CAD. This is likely to be at the expense of more established treatments such as CABG. The difference in CTO-PCI practice observed between Japan and North America is not easily explained.
Contributing factors may be differences in study period, unclear guidelines, misrepresentation of safety/efficacy evidence supporting the use of CTO-PCI, neglect of the evidence supporting more established treatments, gatekeeper effect, as well as the lack of policies by health authorities.
In this article we provide evidence to support the view that CABG surgery remains the gold standard for the treatment of CTOs in patients with isolated left main stem (LMS), left anterior descending (LAD) or with CTOs in the context of multi-vessel CAD. In addition we explore safety and efficacy concerns behind the widespread use of CTO-PCI.
Baseline determinants of health outcome and decision making in patients with CTOs
For patients with CTO the decision making process should be based on a meticulous evaluation of the coronary anatomy, the complexity of each patient risk profile, the support of the Heart Team, the reference to evidence-based medicine, and on a fully informed patient.
Clinical and cardiac specific variability of patients with CTOs
Patients with CTOs may have a complex risk profile with higher incidence of diabetes mellitus, multi-vessel disease (MVD), LMS coronary disease, diffuse coronary and peripheral vascular disease, and aggressive calcification of their coronary vessels resulting in higher SYNTAX scores 16, 17 . Additional variability may derive from differences in cardiac risk factors such as presence of single or multi-vessel CAD, extensive left ventricular (LV) scarring and/or residual viability/hibernation in the CTO territory, which may reflect on LV function 18, 19 , ischemic burden (if any), and symptoms status (asymptomatic or chronic stable angina) 20, 21 .
Coronary anatomical variability of CTOs
The anatomical assessment of CAD is based on coronary angiography. In addition, the length of CTOs may vary from few millimetres to > 40mm with long CTOs often associated with scarred/infarcted myocardium and associated with worse health outcome 23 . Long CTOs may at times affect coronary bifurcations of sizable branches and this may have implications on the treatment to select to ensure a complete and effective revascularisation of both branches.
Pathophysiology of stable CAD and CTOs
Severe atherosclerotic CAD is associated with endothelial dysfunction affecting the ability to increase blood flow in response to changing metabolic demands, hence leading to myocardial ischaemia 25, 26 . Spontaneous rupture of severely stenotic plaques and thrombotic complications often lead to MI and sudden death 27, 28 , although they may also go clinically undetected due to healing of the ruptured plaque 29, 30 . However, MI and acute coronary syndromes more often occurs by rupture/thrombosis of mild/moderate plaques, suggesting that "in plaque" events play a role in sudden death and fatal MI 29, 31 . Hence, methods of coronary revascularisation should minimise the chances of additional iatrogenic "in plaque"
or distal events. Given that CTO-PCIs are "in-plaque" procedures determining iatrogenic plaque ruptures during prolonged wiring/ballooning/stenting they can lead to acute thrombosis and/or distal coronary microembolisation. Hence these procedures pose potential safety concerns which need proper investigating.
Evidence supporting the use of CABG for the treatment of CTOs in patients with

LMS, LAD, and MVD
Impact of CABG on revascularisation rates, health outcome and graft patency rates
Historically, the treatment of CTOs has been assigned to CABG or medical therapy [5] [6] [7] [8] [9] This outcome is confirmed by a very large recent study with more than 1.5 million CABG patients also from USA 34 .
In the SYNTAX trial the superiority of CABG vs PCI was obvious at 12-month for the primary outcome major adverse cardiac or cerebrovascular events (MACCE) 16 CABG surgery can achieve very high rate of completeness of revascularisations, regardless of the incidence of CTO lesions and of levels of SYNTAX score. This is not the case for PCI.
The rate of MACCE events at 5-year between the CABG and PCI registries, both with higher incidence of CTOs compared to the trial cohorts, favoured disproportionately CABG (23.2%
vs. 49.2%, respectively) 35 .
Other studies focusing on CTOs patients also demonstrate excellent outcomes associated with the use of CABG. Data are available comparing the two subsets of CTO patients entered in the SYNTAX trial 35 . The trial included a total of 543 CTO patients (CABG n-266; PCI n=277) with similar coronary distribution and SYNTAX score between these two cohorts.
The overall success rate for treatment of CTOs (including cases not attempted) was 68.1% vs.
49.4%, CABG vs PCI respectively. In the CABG subset 97.8% CTOs were treated with at least one arterial graft. In the PCI subset the procedure was staged in 20.3% of patients, with use of an average of 5.0±2.2 stents per patient (range 8-80mm of stents). In these sub-groups health outcome at 12 months showed a significant difference in MACCE events at 12.2% vs.
18.9% CABG vs. PCI respectively 16 .
Banerjee et al. 23 CTO vs. non-CTO groups). However, longer CTO length (>40 mm) was associated with higher mortality at one year. The need for repeat revascularization (including PCI) was higher in the non-CTO group, although no difference was observed in need for repeat CABG (5.0%
vs. 5.1%, CTO vs. non-CTO groups, respectively). Freedom from cardiac death at 1-year was significantly lower in the CTO group (p < 0.048). These findings are in keeping with the report by Fefer et al. 36 in a series of 405 consecutive CABG patients including 174 cases with a total of 221 CTOs, of which 86% were successfully bypassed (100% LAD-CTO bypassed successfully).
Effectiveness of LIMA-LAD graft and long-term patency rates of CABG
There is evidence in the literature that CTO-PCI is being used extensively in patients with CTO lesions of the LAD alone or in the context of MVD 2 . This is surprising when considering that the patient benefits associated with the LIMA-LAD graft have been transformational with limited in-hospital risks, improved life expectancy benefits, and very high patency rates (92-95%) at 15-20 years 37, 38 . The benefits of the LIMA-LAD grafts questions the reasons for undertaking CTO-PCI of the LAD in symptomatic patients.
Confirmatory studies demonstrate improved 10-year actuarial survival rates associated with the use the LIMA conduit as opposed to saphenous vein grafts (SVG) only, making the pedicled LIMA-LAD graft the dogma of modern coronary surgery. In keeping with these findings, other confirmatory studies suggest that not using a LIMA-LAD graft is associated with an increased risks of late MI, recurrence of angina, and need for repeat revascularisation 37, 38 .
The excellent long-term patency rate of the LIMA-LAD graft is confirmed also for patients with CTO-LAD (Figure 2A and 2C 41 .
CABG revascularisation of CTOs with SVG grafts
One of the arguments against surgical intervention for single vessel CAD other than LAD disease is the long-term patency rates of saphenous vein grafts (SVGs). Historical data on SVG grafts long term patency rate suggest that approximately 50% of these grafts become occluded within 10-years 37, 38 . This also means that the remaining 50% SVG grafts remain patent beyond the 10-year cut off ( Figure 2B ). However, more recent reports suggest SVGs patency rates of as high as > 80% at long-term follow up in some centres possibly as result of improved management of postoperative anti-platelet function, refinement of surgical approaches with utilisation of less invasive SVG harvesting techniques 42 , and the a better understanding of the mechanisms involved in developing vein grafts inflammation and intimal hyperplasia [43] [44] [45] . For example, the 7-year patency rates of the BHACAS trials assessed with multi-slice CT scans showed an overall 89% patency rates in both the on-pump and offpump groups despite utilisation of SVGs for approximately 75% of grafts 46 .
Efficacy of CABG for CTOs affecting coronary vessels other than the LAD
For the rare condition of LMS-CTO (0.04-0.4% of all CTOs) small surgical series have been reported with excellent revascularisation rates and late outcome with successful use of LIMA-LAD grafts [47] [48] [49] . Successful revascularisation rates are reported at 80-90% for CTOs of LCX, with >80% of patients having all multiple CTOs treated successfully and concomitantly 23, 36 . Fefer et al. 36 showed that presence of CTOs was not associated with increased mortality by multivariate analysis. The study also suggested that failure to revascularize a non-LAD CTO was not associated with adverse long-term outcome.
CTOs requiring endarterectomy during CABG
Occasionally, surgeons have had to deal with complex, distal and long CTO lesions by performing more invasive procedures such as endarterectomy. Gill et al. 50 reported a small series of 74 patients undergoing LIMA-LAD, in whom 25 patients received endarterectomy to remove the CTO lesion prior to positioning the LIMA graft. This approach was associated with high inotropic requirement in 25% of the patients and a 6.7% incidence of postoperative MI. This study nonetheless is unfortunately too small for any meaningful considerations.
However, it is wort noting that the rates of these postoperative complications were unusually high by routine CABG standards, whilst supporting the concept that increased coronary invasiveness is associated with worse cardiac specific outcome.
Evidence supporting the use of PCI-stenting for the treatment of CTOs in patients with LMS, LAD, and MVD
The use of CTO-PCI is wide spreading due to advances in PCI technologies including "parallel" and "seesaw" wire techniques, balloon anchoring, sub-intimal tracking and re-entry (STAR), retrograde approach, contralateral injection, and intravascular ultrasound guidance 51 .
Claims of PCI efficacy for CTO-PCIs are mostly based on observational studies comparing successful vs failed CTO-PCI recanalizations with misrepresentation of the iatrogenic effects determined by CTO-PCI undertaking in the cohorts suffering failed procedures.
Comparing successful vs failed CTO-PCIs: a fair trade-off?
Comparing successful versus failed PCI-stent for CTOs does not provide evidence of the efficacy of CTO-PCI versus other forms of revascularisation. Rather, this approach may allow ascertaining potential safety concerns based on the severity and rates of serious complications observed in the failed CTO-PCI groups. We simply do not know what would have happened to the patients suffering a failed CTO-PCI, had they been offered instead more established treatments like medical therapy or CABG. Surprisingly, despite the lack of comparisons versus real control interventions, the outcome of the successful CTO-PCI procedures is being wrongly marketed as evidence of efficacy. Jones et al. 52 reported retrospectively the outcome of 6996 patients treated with PCI-stent, of whom 836 (11.9%) previous studies it is fair to maintain that this was only a feasibility/pilot study with no control group and that the potential efficacy of the new stent will need to be ascertained in a
proper head to head comparison in future trials 57 .
Late functional or angiographic evidence supporting the use of CTO-PCI
Lack of functional or angiographic data is a consistent issue with CTO-PCI reports in the literature. However, anecdotal cases of early re-occlusions post CTO-PCI requiring surgical intervention are increasingly being discussed among surgeons ( Figure 3A-D) . Valenti and colleagues 58, 59 reported two series of CTO-PCI procedures undertaken in 258 and in 1005 consecutive patients. On-table recanalization success rates were 81% and 77% respectively.
Six-nine month angiographic follow-up was available for 80% of all successful CTO-PCI procedures in both series. This showed an overall incidence of re-occlusion and/or restenosis >50% in 23.3% and 21% of patients respectively. This indicates an overall 6-9 month procedural failure (on-table failed recanalization plus late re-occlusion/restenosis) of 42.3%
and 44% respectively. This angiographic data seems to raise a word of caution on the effectiveness of CTO-PCI and hopefully more robust evidence will soon be available in this area 56, 57 .
One recurrent claim in CTO-PCI retrospective reports is that the procedure leads to improvement in angina symptoms, LV function and survival 20, 21 . This is based on the assumption that CTO-PCI increases the blood supply to the ischemic CTO territory (often already supplied by collaterals). However, this assumption remains unsubstantiated. In the Occluded Artery Trial (OAT) 2166 stable CAD patients with total occlusion of the infarctrelated artery 3 to 28 days after MI were randomised to PCI stenting plus optimal medical therapy versus optimal medical therapy alone. This trial did not show any benefit associated with the use of PCI-stenting for the composite of death, myocardial re-infarction, or New
York Heart Association (NYHA) class IV heart failure at 4-years (17.2% in the occluded artery group and 15.6% in the medical therapy group (HR 1.16; 95% CI, 0.92 to 1.45;
P=0.20) while death rates were also similar (9.1% vs. 9.4%). Although the total occlusions of the OAT trial were not > 3 month chronic, hence probably easier to reopen, it's worth noting that the use of PCI-stenting was not superior to medical therapy alone. In the FACTOR trial 60 125 patients with ischemic myocardium were treated with CTO-PCI. They completed the Seattle Angina Questionnaire at baseline and 1-month post procedure. At 1-month, in asymptomatic patients no benefit was associated to the use of CTO-PCI. This highlights the limitation of this approach in patients with ischemic myocardium but without angina, for whom a measure of prognostic outcome would be of greater value. In the COURAGE trial the impact on ischemic myocardium measured by nuclear imaging did not improve the midterm prognosis in the PCI-stent group 6 . Accordingly, Stergiopoulos et al. 61 in a meta-analysis of trials in stable CAD patients with ischemic myocardium highlight that the use of PCI-stent did not improve the observed rates of death, MI, angina, and need for revascularisation compared to medical therapy. Similarly, others have suggested that CTO-PCI to LV hibernated/dysfunctional territories lead only to marginal, if any, effect even when using a sensitive imaging tool like MRI 10 . Nevertheless, the evidence of LV impairment triggered by failed CTO-PCIs is of higher concern given the excessive rate of coronary dissection, perforations, and distal micro-embolizations reported 62, 63 .
Another argument used is that successful CTO-PCIs improve prognosis compared to failed CTO-PCIs. This claim is surprising, given that CTO-PCI is the direct determinant of serious complications in the failed cohorts. One could simply argue the other way around that CTOPCIs in fact worsen the prognosis of patients undergoing failed procedure. The argument used by CTO-PCI promoters is based on pooled observations 64 and is questionable as often retrospective pooled comparisons cannot take into account key differences in baseline characteristics between pooled groups due to lack or non-homogeneous data available. This is supported by the analysis of patients from the CREDO-Kyoto Registry (1192 successful CTO-PCIs vs. 332 failed CTO-PCIs), which in presence of homogenous baseline data available for the entire cohort suggests that at 3-year there is no difference in all-cause mortality between groups 2 .
Invasiveness of CTO-PCI
CTO-PCIs are very invasive procedures impacting both at systemic and at coronary/cardiac specific levels. They are associated with very long procedural and fluoroscopic times as well as increased use of contrast volumes and related incidence of renal failure [52] [53] [54] . Poor tolerance by sedated patients, complex risk profile, and prolonged procedural time are regarded as factors triggering the adoption of general anaesthesia instead of sedation 65 . The need for significant and prolonged platelet inhibition after CTO-PCI is not a trivial factor. Evidence suggests that patients with extensive coronary stents undergoing non-cardiac surgery early after stenting are at increased risk of MACE, with perioperative mortality rates as high as 85% being reported due to different reasons including stent thrombosis as a result of stopping or changing antiplatelet regime 66, 67 .
One of the most concerning aspect of CTO-PCI is its excessive coronary invasiveness, which is unprecedented. This causes serious complications including coronary perforation, dissections, tamponade, acute thrombotic events, LV impairments, and peripheral vascular injuries. The occurrence of these complications is not surprising and probably should be expected when considering the level of coronary invasiveness applied during CTO-PCI, the off-label use of stents designed for non CTO lesions, the CTO-PCI related activation of patho-physiological mechanisms triggering acute thrombosis, chronic inflammation as well as repeated intra-coronary micro-embolization in the relevant viable myocardial territory which may impair LV function in line with the principles of established models of chronic heart failure 68 . Patel et al. 55 in a meta-analysis of 18,061 pooled CTO patients with 18,941
target CTOs reported a rate of coronary perforation of 3.65% vs. 10.70%, in successful vs failed CTO-PCIs (P<.001), with a related incidence of tamponade of 0% vs. 1.65%
(P <.001). These numbers equal to hundreds of patients suffering poor health outcome caused by CTO-PCI procedures. This is not an isolated observation. Mehran et al. 62 reported an analysis from the Multi-national CTO Registry in 1791 CTO patients. The rates of coronary dissection and perforation were of 4.3% and 1.7% and of 9.4% and 7.4% in successful vs.
failed CTO-PCI, respectively. Of note, the mortality rate of the failed CTO-PCI cohort was not reported. High rates of MI and need for emergency CABG were reported, but deaths after emergency CABG were omitted (to be ascribed by intention to treat to the failed CTO-PCI cohort). Excessive rates of serious complications have been reported by Japanese centres.
Kimura et al. 69 in a series of 1014 CTOs in 943 patients compared the antegrade (n=733) vs retrograde (n=277) approaches. They reported extremely high rates of coronary dissection (14.7% vs. 10.1%), perforation (8.2% vs. 13%), and distal myocardial embolization (3.7% vs.
1.4%) in the antegrade vs retrograde cohorts respectively.
The goal of CABG surgery is to position the anastomosis in a health coronary segment distal to the blockage ( Figure 4A ). Conversely, the goal of CTO-PCI stenting is to perform a variety of "in blockage procedures" including complex antegrade/retrograde wiring, high pressure ballooning, and multiple stenting (i.e. leaving behind foreign bodies triggering continuously in-plaque chronic thrombosis and inflammation) to achieve recanalization ( Figure 4B ). These technical differences between CABG and CTO-PCI are not trivial and might explain the rates of serious complications reported during CTO-PCI stenting as well as the higher rates of early recurrence, cardiac specific complications, and worse late health outcome. Of note, when referred for emergency CABG failed CTO-PCIs present with rather dramatic findings ( Figure 4C ) often associated with deaths and/or major complications that are unlikely to be retained in the CTO-PCI cohorts of the observational studies available in the literature 62, 63, 69 .
Conclusions
Available evidence-based medicine derived from the COURAGE and OAT trials suggest that in patients with stable CAD or in those with occluded coronary arteries < 3 months the use of PCI-stenting is not superior to medical therapy alone. The ongoing DECISION-CTO and the EuroCTO trials once completed will help clarifying the impact of CTO-PCI versus medical therapy alone in these patients.
The use of CTO-PCI is spreading quickly worldwide across CABG anatomical categories such as LMS, LAD, and MVD disease despite the establishment of the Heart Teams and despite strong evidence from large sub-analyses of CABG vs. PCI-stent trials and from large database registries supporting the superiority of CABG. The recent evidence-based medicine SYNTAX trial confirms the superiority of CABG at 1 and 5 years in MACCE events across all the patient categories including large subsets of CTO patients.
The global promotion of CTO-PCI as an effective procedure across all CAD anatomical categories is of concern as it is based on questionable evidence derived only from "comfortable" comparisons between successful vs. failed CTO-PCI procedures with no controls. In fact, these "comfortable" comparisons suggest that CTO-PCI might be causing significant injury to patients suffering procedural failures. This key safety concern seems to be grossly misrepresented in the available CTO-PCI literature while a disproportionate emphasis of efficacy seems to be based on soft findings such as on table successful recanalization, which is neither synonymous of improved myocardial perfusion/function nor evidence of late patency. In this context, the undertaking of randomised trials comparing CABG vs. CTO-PCI in patients with LMS, LAD, and MVD does not seem to be justified on pure clinical grounds at this stage.
On the ground of the available evidence we strongly suggests that all CTO patients should be carefully discussed at multidisciplinary Heart Team meetings including a balanced professional representation of surgeons and interventional cardiologists, bearing in mind that at this stage for CTO patients with LMS, LAD, and MVD disease CTO-PCI may have a role only for a certain type of sick population deemed to be not suitable for CABG.
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